Advanced Search: NSCLC

For more information about any of the clinical trials listed on this site, call 314-747-7222 or 800-600-3606 toll free or email Patient_Care_Coordination_Center@bjc.org.

Select Basic Search to view clinical trials grouped by category and Advanced Search to be able to further narrow search results.

 

202012016

A Phase 1b, Multicenter, 2-Part, Open-Label Study of DS-1062a in Combination with Durvalumab in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer without Actionable Genomic Alterations and Previously Treated with Platinum-based Chemotherapy with or without Prior Immunotherapy

202104110

A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients with Previously Treated Non-Squamous NSCLC

202108029

A phase ll, open-label, multicenter study evaluating the safety and efficacy of neoadjuvant and adjuvant tiragolumab plus atezolizumab, with or without platinum-based chemotherapy, in patients with previously untreated locally advanced resectable stage ll, lllA, or select lllB non-small cell lung cancer

201905035

A Single-Arm Phase II Study with a Safety Lead-in of Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy with Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB, IIIA, and Select IIIB and IIIC Non-small Cell Lung Cancer

202103029

A Phase 1/2a, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-3312 in Combination with Pembrolizumab or Binimetinib in Adult Patients with Advanced Solid Tumors

202103095

A Phase 1 first in human study evaluating safety and efficacy of ABBV-637 as either monotherapy or in combination in adult subjects with relapsed and refractory solid tumors

202003170

Master Protocol to Assess the Safety and Recommended Phase 2 Dose of Next Generations of Autologous Enhanced NY-ESO-1/ LAGE-1a TCR Engineered T-cells, alone or in combination with other agents, in Participants with Advanced Tumors

202103114

A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) as a Single Agent and In Combination with Defactinib (FAK Inhibitor) in Recurrent KRAS-Mutant (KRAS-MT) Non-Small Cell Lung Cancer (NSCLC)

202105161

A Phase 1, Open-Label, Dose-Escalation, Dose-Finding Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects with Advanced Solid Tumors

202003168

A Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib vs Concurrent Chemoradiation Therapy Followed by Durvalumab in Participants with Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer (NSCLC)